01.07.2023 - 00:00:00

New Study Reveals Potential Biomarker for Melanoma Treatment Response

In the newest volume of the Nature Cancer Journal, there is a new paper by Alexander Rösch (A11) and his group. Their paper highlights the significance of interleukin (IL)-17A in BRAFV600-mutated melanomas. The study reveals elevated IL-17A levels in melanoma patients' blood, particularly in those responding well to dual immune checkpoint inhibition (ICI) treatment. This indicates IL-17A's potential as a future biomarker for patient stratification. Dual ICI therapy, combining anti-PD1 and anti-CTLA-4 treatments, is found to benefit patients with higher IL-17A levels, boosting the body's tumor defense mechanism